3-methyl-7-(2-butyn-1-yl)-8-[3-(tert-butyloxycarbonylamino)-piperidin-1-yl]-3,7-dihydro-1H-purine-2,6-dione | 668272-43-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 3-methyl-7-(2-butyn-1-yl)-8-[3-(tert-butyloxycarbonylamino)-piperidin-1-yl]-3,7-dihydro-1H-purine-2,6-dione
• 英文别名: 3-methyl-7-(2-butyn-1-yl)-8-[3-(tert-butyloxycarbonylamino)-piperidin-1-yl]-xanthine；3-methyl-7-(but-2-ynyl)-8-[3-(tert-butoxycarbonylamino)-piperidin-1-yl]-xanthine；3-methyl-7-(but-2-yn-1-yl)-8-[3-(tert-butoxycarbonylamino)-piperidin-1-yl]-xanthine；tert-butyl N-[1-(7-but-2-ynyl-3-methyl-2,6-dioxopurin-8-yl)piperidin-3-yl]carbamate
• CAS: 668272-43-3
• 化学式: C₂₀H₂₈N₆O₄
• 分子量: 416.48
• InChiKey: MKEXJLGKOKCUEB-UHFFFAOYSA-N

物化性质

• 熔点：
  235-237 °C
• 密度：
  1.32±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  30
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  109
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-chloromethyl-4-phenylamino-quinazoline 、 3-methyl-7-(2-butyn-1-yl)-8-[3-(tert-butyloxycarbonylamino)-piperidin-1-yl]-3,7-dihydro-1H-purine-2,6-dione 在 caesium carbonate 作用下， 以 DMF (N,N-dimethyl-formamide) 为溶剂， 反应 3.67h， 以65%的产率得到1-[(4-phenylamino-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(tert-butyloxycarbonylamino)-piperidin-1-yl]-xanthine
  参考文献：
  名称：

  [DE] 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINE, DEREN HERSTELLUNG UND DEREN VERWENDUNG ALS DPP-IV HEMMER
  [EN] 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINE, THE PRODUCTION THEREOF AND THE USE IN THE FORM OF A DPP INHIBITOR
  [FR] 8-[3-AMINO-PIPERIDINE-1-YL]-XANTHINES, LEUR FABRICATION ET LEUR UTILISATION COMME INHIBITEUR DE DPP-IV

  摘要：

  本发明涉及通式（I）中的取代黄嘌呤，其中R如权利要求1所定义，其互变异构体，立体异构体，混合物和盐，具有有价值的药理特性，特别是对二肽基肽酶-IV（DPP-IV）酶活性的抑制作用。

  公开号：

  WO2005085246A1

文献信息

• METHOD FOR PREPARING AN IMPORTANT INTERMEDIATE OF LINAGLIPTIN
  申请人：2Y-CHEM, LTD.

  公开号：US20150274728A1

  公开（公告）日：2015-10-01

  The present invention discloses an improved process for preparing an important intermediate of linagliptin. In particular, disclosed are a process for preparing a compound V which is an important intermediate of linagliptin and has the structure V, and an industrial process of preparing linagliptin having excellent chemical and optical purities, which is an inhibitor of dipeptidyl peptidase-4 (DPP-IV), from the compound V. The process employs a phase-transfer catalyst, is high in yield, easy and simple to handle, environmentally friendly, suitable for industrial mass production, and can be implemented by a “one-pot process”.

  本发明公开了一种改进的制备利那格列汀重要中间体的工艺。具体公开了一种制备化合物V的工艺，该化合物V是利那格列汀的重要中间体，具有结构V，并且从化合物V中制备出具有优异化学和光学纯度的利那格列汀的工业工艺，利那格列汀是二肽基肽酶-4（DPP-IV）的抑制剂。该工艺采用相转移催化剂，产率高，易于操作和简单处理，环保，适合工业大规模生产，并且可以通过“一锅法”实施。
• 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
  申请人：Himmelsbach Frank

  公开号：US20050234108A1

  公开（公告）日：2005-10-20

  The present invention relates to substituted xanthines of general formula wherein R is defined as in claim 1 , the tautomers, the stereoisomers, the mixtures thereof and the salts thereof, which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

  本发明涉及通式所示的取代黄嘌呤，其中R如权利要求书中所定义，其互变体、立体异构体、其混合物和盐具有有价值的药理特性，特别是对酶二肽基肽酶-IV（DPP-IV）活性的抑制作用。
• 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS
  申请人：Himmelsbach Frank

  公开号：US20080255159A1

  公开（公告）日：2008-10-16

  The present invention relates to substituted xanthines of general formula wherein R 1 to R 3 are defined as in claims 1 to 16 , the tautomers, the stereoisomers, the mixtures, the prodrugs thereof and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

  本发明涉及一般式的取代黄嘌呤，其中R1至R3的定义如权利要求1至16所述，其互变异构体、立体异构体、混合物、前药和盐具有有价值的药理特性，特别是对酶二肽基肽酶-IV（DPP-IV）的抑制作用。
• 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
  申请人：Boehringer Ingelheim Pharma GmbH & Co. KG

  公开号：US20040097510A1

  公开（公告）日：2004-05-20

  The present invention relates to substituted xanthines of general formula 1 wherein R 1 to R 3 are defined as in claims 1 to 16, the tautomers, the stereoisomers, the mixtures, the prodrugs thereof and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPI-IV).

  本发明涉及一般式1的取代黄嘌呤，其中R1至R3的定义如权利要求1至16所述，其互变异构体、立体异构体、混合物、前药及其盐具有有价值的药理学特性，特别是对酶二肽基肽酶-IV（DPI-IV）的抑制作用。
• Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
  申请人：Boehringer Ingelheim Pharma GmbH & Co. KG

  公开号：US20040138215A1

  公开（公告）日：2004-07-15

  The present invention relates to substituted xanthines of general formula 1 the tautomers, the stereoisomers, the mixtures thereof, the prodrugs thereof and the salts thereof, which have valuable pharmacological properties, particularly an inhibitory effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

  本发明涉及通式1的取代黄嘌呤，包括其互变异构体、立体异构体、混合物、前药及其盐，该类化合物具有有价值的药理学性质，特别是对二肽基肽酶-IV（DPP-IV）酶活性具有抑制作用。